PolyPid Ltd.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Dikla Czaczkes Akselbrad
- Full Time Employees
- 75
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 18 Hasivim Street Petah Tikva HM Israel 4959376
- IPO Date
- Jun 26, 2020
- CIK
- 0001611842
- Website
- polypid.com
- Similar Companies
- Business
- PolyPid Ltd. (Nasdaq: PYPD) is a clinical-stage biopharmaceutical company that develops, manufactures and commercializes novel, locally administered prolonged-release therapeutics using its proprietary PLEX (Polymer-Lipid Encapsulation matriX) technology platform, which enables controlled drug delivery over days to months directly to surgical sites for conditions including infection, pain, inflammation and cancer; lead product candidate D-PLEX100 delivers doxycycline antibiotic to prevent surgical site infections (SSIs) in abdominal colorectal surgery, while OncoPLEX targets intra-tumoral cancer treatment in preclinical development, with the PLEX platform accommodating small molecules, proteins, peptides and nucleic acids. Founded in 2008 and headquartered in Petach Tikva, Israel, the company operates globally with a focus on surgical outcomes and healthcare-acquired infections like SSIs, targeting surgeons, hospitals and patients in the United States and Europe through planned NDA and MAA submissions. In 2025, PolyPid received a positive DSMB recommendation to conclude its pivotal SHIELD II Phase 3 confirmatory trial for D-PLEX100 at 800 patients with top-line results anticipated in Q2, raised $14.5 million in a PIPE financing led by institutional investors extending cash runway to Q3 2025, initiated a research and development collaboration with ImmunoGenesis Inc. leveraging PLEX and STING agonist technology for solid tumor treatments, and advanced commercialization preparations alongside U.S. partnership discussions.
PolyPid, Azurity sign surgical site infection drug deal
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid Announces Exclusive Partnership with Azurity Pharmaceuticals for the Commercialization of D-PLEX₁₀₀ in the U.S. and Canada
PolyPid Completes New Drug Application Submission to FDA for D-PLEX₁₀₀
PolyPid to Participate in the Craig-Hallum 23rd Annual Institutional Investor Conference
PolyPid Q1 Earnings Call Highlights
PolyPid Ltd. (PYPD) Q1 2026 Earnings Call Transcript
PolyPid Provides Corporate Update and Reports First Quarter 2026 Financial Results
PolyPid to Report First Quarter 2026 Financial Results and Operational Highlights on May 13, 2026
PolyPid to Present Data from SHIELD II Phase 3 Trial Demonstrating Reduced Severity of Surgical Site Infection at Surgical Infection Society 2026 Annual Meeting
BeOne Medicines (NASDAQ:ONC) & PolyPid (NASDAQ:PYPD) Critical Analysis
PolyPid to Present New Phase 3 SHIELD II Data Demonstrating D-PLEX₁₀₀ Sustained Local Release at ESCMID Global 2026
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Rating of “Moderate Buy” from Analysts
PolyPid (NASDAQ:PYPD) Stock Price Up 3.3% – Still a Buy?
PolyPid Initiates D-PLEX₁₀₀ NDA Submission to the FDA
PolyPid Ltd. (NASDAQ:PYPD) Receives Consensus Recommendation of “Moderate Buy” from Analysts
PolyPid Receives PDUFA Fee Waiver from FDA for D-PLEX₁₀₀'s New Drug Application
PolyPid Announces Participation in Upcoming Investor Conferences
PolyPid Q4 Earnings Call Highlights
PolyPid Ltd. (PYPD) Q4 2025 Earnings Call Transcript